AACR 2026 Poster 1814

An Integrated DMPK and Bioanalytical Platform for Comprehensive Characterization of Antibody-Drug Conjugates (ADCs)

Kefeng Gong, Xinhe Feng, Zhengyi Hua, Yanting Ma, Rui Wang, Xiaolong Tu, Luke Yu

Research featured here highlights a robust testing platform designed to evaluate Antibody-Drug Conjugates (ADCs). Because these therapies combine targeted antibodies with potent toxins, understanding their stability and how they break down in the body is essential for safety and effectiveness.

The study compared three clinically relevant ADCs: T-DXd, T-DM1, and EV, using a versatile bioanalytical toolbox to monitor how different designs impact performance. While T-DXd and T-DM1 demonstrated high stability across species, EV showed significant toxin release specifically in mouse plasma due to enzyme activity not present in humans.

By tracking the Drug-to-Antibody Ratio (DAR) and "free payload" levels, the platform provides critical data to de-risk the development path from discovery to preclinical stages. 

Download this Poster to Discover:

• Strategic Evaluation Framework: Learn how a holistic DMPK strategy integrates in vitro drug stability and in vivo PK/PD studies to characterize complex therapeutics.
  
• Impact of Design on Stability: Discover how specific linker types and payloads — such as cleavable versus non-cleavable designs — directly influence payload release and drug-to-antibody ratio (DAR) across different species.
• Comparative Data: View direct side-by-side analysis of how different linker and payload designs affect drug behavior in vivo.
  

Download the Poster Now!